Role of Targeted Therapies in Management of Metastatic Urothelial Cancer in the Era of Immunotherapy
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11864-019-0665-y.pdf
Reference88 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
2. Koshkin VS, Grivas P. Emerging role of immunotherapy in advanced urothelial carcinoma. Curr Oncol Rep. 2018;20(6):48.
3. •• Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26 Landmark phase 3 trial of pembrolizumab vs. salvage chemotherapy in mUC.
4. • Powles T, Duran I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomized controlled trial. Lancet. 2018;391(10122):748–57 Landmark phase 3 trial of atezolizumab vs. salvage chemotherapy in mUC.
5. Grivas P, Laliberte F, Doleh Y, et al. Economic burden of select adverse events in patients with metastatic urothelial cancer treated with first-line systemic therapy. J Clin Oncol. 2019;37(7_suppl (March 12,019)):363. https://doi.org/10.1200/JCO.2019.37.7_suppl.363 .
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Tumor expression of Nectin-1–4 and its clinical implication in muscle invasive bladder cancer: An intra-patient variability of Nectin-4 expression;Pathology - Research and Practice;2022-09
2. Combination of T-DM1 and platinum-based chemotherapy in patient-derived xenograft models of muscle-invasive bladder cancer;IRAN J BASIC MED SCI;2022
3. Mutually exclusive mutation profiles define functionally related genes in muscle invasive bladder cancer;PLOS ONE;2022-01-24
4. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy;Urology;2021-11
5. Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab;Clinical and Translational Oncology;2021-10-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3